Tekmira to supply Ebola drug to investigators in Africa; Novartis hands MorphoSys a cancer drug-related payment;

@FierceBiotech: Achillion shares rocket up as hep C drug scores a quick 6-week cure. News | Follow @FierceBiotech

@JohnCFierce: My schedule at #JPM15 is now officially packed. Thanks for all the invites. The industry is headed to San Fran. | Follow @JohnCFierce

@DamianFierce: Here's the packaging for $ABBV's Viekira, with handy instructions for each of its four pills. Image | Follow @DamianFierce

> Tekmira Pharmaceuticals ($TKMR) says it will supply its Ebola drug to investigators mounting a study in West Africa. Release

> MorphoSys says that it landed a payment from Novartis ($NVS) in connection with the Phase I study of a HuCAL antibody for cancer. Story

Medical Device News

@FierceMedDev: ICYMI Friday: Private equity firm backs Sonoma Orthopedic with $12M to get ankle implant to market. Story | Follow @FierceMedDev

@EmilyWFierce: ICYMI: U.S. appeals court reduces damages Zimmer must pay Stryker in surgical cleaning wand patent suit. Reuters story | Follow @EmilyWFierce

> Roche continues diagnostics winning streak with Bina Technologies acquisition. News

> NIH launches crowdsourcing challenge to commercialize its neurological medical devices. More

> Medtronic reaches another milestone in developing its artificial pancreas. Article

Pharma News

@FiercePharma: New deer vaccine against mad-cow-like disease may help people too. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICMYI from FiercePharmaManufacturing: AstraZeneca targets U.K. plant for closure. Report | Follow @EricPFierce

@CarlyHFierce: #ICYMI: Deal-happy Actavis eyes Spain's Almirall for European growth. Story | Follow @CarlyHFierce

> AstraZeneca CEO says Pfizer won't come back. Oh, and that $45B goal? It's a stretch. Report

> Sorry, Gilead. AbbVie cuts exclusive hep C deal with Express Scripts. More

CRO News

> Evotec banks $10M from its risk-sharing research projects. News

> PPD partners up with ERT for data collection. Story

> WuXi reaches into the biopharma hubs of Boston and San Francisco. More

> Poland's KCR expands its Euro reach with latest deal. Article

> After CEO's death, Health Decisions brings in a Quintiles vet to lead its transition. Report

Animal Health News

> Zoetis hikes dividend under continued pressure from activist investor Ackman. Report

> Aratana Therapeutics starts new canine study; reports good results on another. News

> Lilly's Elanco disputes local paper's allegations of unsafe pet meds. More

> Putney continues winning streak with launch of generic chewable Rimadyl. Article

> Bayer casts off equine drugs with 'no strategic relevance' to Sanofi's Merial. Story

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.